Table 2.
Demographic profiles in different genotypic groups among patients and controls.
| Variable | Patients (N = 625) | Controls (N = 400) | ||||||
|---|---|---|---|---|---|---|---|---|
| TT (N = 544) |
TC (N = 81) |
Statistic | p | TT (N = 347) |
TC (N = 53) |
Statistic | p | |
| Age (years) | 44.91 ± 10.21 | 45.84 ± 10.81 | 0.77 | 0.44 | 44.67 ± 13.53 | 45.15 ± 13.44 | 0.24 | 0.81 |
| Gender (male) | 447 (82.2%) | 66 (81.5%) | 0.17 | 0.92 | 135 (38.9%) | 22 (41.5%) | 0.13 | 0.72 |
| Education (years) | 8.42 ± 3.75 | 8.70 ± 2.93 | 0.67 | 0.50 | 9.94 ± 5.80 | 8.38 ± 3.86 | 1.90 | 0.06 |
| BMI | 23.97 ± 4.52 | 23.99 ± 4.00 | 0.04 | 0.97 | 25.10 ± 4.20 | 25.50 ± 4.64 | 0.62 | 0.53 |
| Onset age | 23.76 ± 6.80 | 30.21 ± 23.17 | 1.01 | 0.28 | − | − | − | − |
| Illness duration (years) | 21.13 ± 9.95 | 21.19 ± 9.64 | 0.05 | 0.96 | − | − | − | − |
| Daily dose (mg/day) (chlorpromazine equivalents) | 390.47 ± 308.32 | 389.49 ± 187.59 | 0.03 | 0.98 | − | − | − | − |
| Antipsychotic treatment duration (months) | 31.27 ± 47.27 | 32.10 ± 42.52 | 0.15 | 0.88 | − | − | − | − |
| PANSS score | ||||||||
| Positive symptoms | 11.95 ± 6.36 | 11.67 ± 5.54 | 0.37 | 0.71 | − | − | − | − |
| Negative symptoms | 19.94 ± 8.62 | 21.48 ± 9.11 | 1.48 | 0.14 | − | − | − | − |
| General psychopathology | 25.10 ± 7.11 | 25.52 ± 7.19 | 0.49 | 0.62 | − | − | − | − |
| Total score | 56.99 ± 16.56 | 58.67 ± 16.17 | 0.85 | 0.40 | − | − | − | − |